The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Self-citationGalanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Self-citationRuthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Self-citationNew Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
Self-citationRecent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
Sava, G., Capozzi, I., Clerici, K., Gagliardi, G., Alessio, E., & Mestroni, G. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006521715400 · Cited by 183
Self-citationBergamo, A., Gagliardi, R., Scarcia, V., Furlani, A., Alessio, E., Mestroni, G., & Sava, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38169-8 · Cited by 160
Self-citationLuigi Messori, A., Orioli, P., Vullo, D., Alessio, E., & Iengo, E. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01121.x · Cited by 143
Self-citationInhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Self-citationZorzet, S., Bergamo, A., Cocchietto, M., Sorc, A., Gava, B., Alessio, E., Iengo, E., & Sava, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38990-6 · Cited by 120
Self-citationGava, B., Zorzet, S., Spessotto, P., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095141 · Cited by 94
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
Self-citationSava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Self-citationPintus, G., Tadolini, B., Posadino, A. M., Sanna, B., Debidda, M., Bennardini, F., Sava, G., & Ventura, C. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03307.x · Cited by 71
Self-citationSanna, B., Debidda, M., Pintus, G., Tadolini, B., Posadino, A. M., Bennardini, F., Sava, G., & Ventura, C. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00218-7 · Cited by 60
Self-citationBergamo, A., Zorzet, S., Gava, B., Sorc, A., Alessio, E., Iengo, E., & Sava, G. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200009000-00012 · Cited by 60
Self-citationRuthenium and Other Non‐Platinum Anticancer Compounds
Bratsos, I., Gianferrara, T., Alessio, E., Hartinger, C. G., Jakupec, M. A., & Keppler, B. K. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch5 · Cited by 54
Self-citationIncrease of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin, M., Bergamo, A., Carotenuto, M. E., Zorzet, S., & Sava, G. (2000) · PubMed · Cited by 39
Self-citationVainchtein, L. D., Rosing, H., Thijssen, B., Schellens, J. H. M., & Beijnen, J. H. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3096 · Cited by 37
Self-citationCasarsa, C., Mischis, M. T., & Sava, G. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.017 · Cited by 21
Self-citationFeatures and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice
Vadori, M., Pacor, S., Vita, F., Zorzet, S., Cocchietto, M., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.09.018 · Cited by 18
Self-citation
Cited by
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Metadata
- Authors
- Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- Investigational New Drugs
- Published
- 2014-10-25
- Volume
- 33
- Issue
- 1
- Pages
- 201-214
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2039150265
- Cited by
- 374
- References
- 34
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.